On June 17, 2021 Harbour BioMed ("HBM", HKEX: 02142) reported that the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer in its open phase I clinical study(Press release, Harbour BioMed, JUN 17, 2021, View Source [SID1234584074]). This study will evaluate the safety, tolerability, PK/PD, and anti-tumor activity of HBM4003 in combination with programmed cell death protein 1 (PD-1) antibody in the treatment of solid tumors. The combined study of HBM4003 and PD-1 antibody/chemotherapy for patients with advanced melanoma and other solid tumors completed the first patient first dosing in March 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Innovative immunology therapeutics bring more effective and safer treatment to patients. I look forward to recruiting more advanced NSCLC patients that may benefit from this treatment," said Professor Shun Lu, Director of Clinical Medicine Department from Shanghai Chest Hospital.

"Lung cancer is by far the leading cause of cancer death, making up almost 25% of all cancer deaths, and there is an urgent need for innovative drugs and therapeutic solutions for lung cancer treatment," said Dr. Wang Jingsong, Founder, Chairman and CEO of Harbour BioMed. "We will continue to accelerate the global development of HBM4003 for multiple cancers, so that we can help cancer patients around the world to live better and longer lives."

About HBM4003

HBM4003 is the fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice. HBM4003 shows enhanced antibody-dependent cell cytotoxicity (ADCC) killing activity and is extremely specific to high CTLA-4 Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug.